Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared an article by ASCO on LinkedIn:
“Despite hormone receptor positive being the most common subtype of breast cancer, for 20 years we’ve seen no innovation in hormone treatments for this disease.
Until 2023, when elacestrant, the first oral SERD, was approved.
And here we are today, with imlunestrant, yet a new oral SERD!
Based on positive phase 3 data, we expect the approval of at least three other innovative endocrine treatments in the near future.
And this is accompanied by huge advancements in targeted treatments, in ADCs, in immunotherapies, with each of these components adding an important piece to the puzzle of curing and managing breast cancer.
Working in oncology is not a light job-
But we’ve never had as much hope, expectations and excitement as in these days.
Here’s to new treatment options for our patients!”
More posts featuring Paolo Tarantino on OncoDaily.